Print Page  |  Contact Us  |  Report Abuse  |  Sign In  |  Join ACAM
CAP Training - Follow Up Questions
Blog Home All Blogs
Search all posts for:   


View all (4) posts »

Vitamin C & Chelation

Posted By Dr. Hiten Shah (, Wednesday, June 29, 2016
  • Is Chelation without vitamin C better or with vitamin C better? Lots of studies show vitamin C acts as prooxident in infusion. Tact was done with vitamin C.     
  • Is there an ACAM protocol of chelation for atherosclerosis?

This post has not been tagged.

Share |
Permalink | Comments (1)

Comments on this post...

Tim Guilford, Chelation Committee says...
Posted Thursday, June 30, 2016
1. Regarding atherosclerosis.
Expert Rev Cardiovasc Ther. 2016 May 5:1-12. [Epub ahead of print]
Chelation therapy to treat atherosclerosis, particularly in diabetes: is it time to reconsider?
Lamas GA, Ergui I

Case reports and case series have suggested a possible beneficial effect of chelation therapy in patients with atherosclerotic disease. Small randomized trials conducted in patients with angina or peripheral artery disease, however, were not sufficiently powered to provide conclusive evidence on clinical outcomes. Areas covered: The Trial to Assess Chelation Therapy (TACT) was the first randomized trial adequately powered to detect the effects of chelation therapy on clinical endpoints. We discuss results and future research. Expert commentary: Chelation reduced adverse cardiovascular events in a post myocardial infarction (MI) population. Patients with diabetes demonstrated even greater benefit, with a number needed to treat of 6.5 patients to prevent a cardiac event over 5 years, with a 41% relative reduction in risk of a cardiac event (p = 0.0002). These results led to the revision of the ACC/AHA guideline recommendations for chelation therapy, changing its classification from class III to class IIb. TACT2, a replicative trial, will assess the effects of chelation therapy on cardiovascular outcomes in diabetic patients with a prior myocardial infarction. We are seeking participating sites for TACT2.

2. Here’s the Medscape perspective on the vitamin question The results look better than the title of the article!
And the comment on controversy is rather revealing of their opinion regarding chelation, while the outcome was positive and the side effects minimal in spite of the "experts" expectation.
7 gm C was added to IV.
No Win for Vitamin Therapy in the TACT Chelation Study
March 15, 2013
When the use of vitamin therapy was combined with chelation and compared with patients who received placebo chelation and placebo vitamins, there was a statistically significant 26% relative reduction in the risk of the primary end point.
In the vitamin arm of TACT [A, B, C, D, E, K, niacin, folate, calcium, magnesium, and zinc, among others], treatment with high-dose vitamin therapy resulted in a statistically nonsignificant 11% relative reduction in the risk of death, MI, stroke, coronary revascularization, or hospitalization for angina when compared with patients who received placebo vitamins. In contrast, the use of active chelation and active vitamin therapy reduced the risk of the primary end point 26% compared with patients randomized to placebo chelation and placebo vitamin therapy.
"The message here really is a cautious message," Lamas told the media during a press conference. "We've moved something from alternative medicine into, perhaps, the reality of scientific inquiry and found some unexpected results that merit further research. We don't think the results of any single trial are enough to carry this novel hypothesis into daily use for patients who have had an acute myocardial infarction."
As reported previously by heartwire , TACT has been mired in controversy. Ethics questions had been raised about the quality of disclosure to patients about possible treatment effects and criticisms leveled at a perceived waste of public money, given that TACT is sponsored by National Center for Complementary and Alternative Medicine (NCCAM) and the National Heart, Lung, and Blood Institute (NHLBI). Enrollment had been slow, and it was stopped and restarted a number of times. When the main results were presented last fall at the American Heart Association annual meeting, experts received the positive results from the chelation arm of the trial with caution, saying the results were "surprising," "intriguing," and "unexpected." Like the vitamin arm of the trial, they said the data raised more questions than answers.
3. And here is an article describing the Anti-oxidant and anti-atherogenic properties of liposomal glutathione in an animal study using oral ReadiSorb Glutathione.
Please note that there is a typo in the abstract, as HDL-induced macrophage cholesterol efflux, was increased by 78% as noted on page e65, not the 19% noted in the abstract.

Permalink to this Comment }

Community Search
Sign In

Forgot your password?

Haven't registered yet?


9/14/2017 » 9/16/2017
ACAM 2017 Annual Meeting

Latest News
Online Surveys